HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by de Zoeten, E. Articles by Cohen, E. P. Search for Related Content PubMed PubMed Citation Articles by de Zoeten, E. Articles by Cohen, E. P.

Treatment of Breast Cancer with Fibroblasts Transfected with DNA from Breast Cancer Cells¹

Edwin de Zoeten^2,*, Victoria Carr-Brendel^2,*, Dubravka Markovic^*, Joyce Taylor-Papadimitriou and Edward P. Cohen^3,*

^* Department of Microbiology and Immunology, University of Illinois, Chicago, IL 60612; and Imperial Cancer Research Fund Laboratories, London, United Kingdom

This investigation was based on the hypothesis that weakly immunogenic, breast cancer-associated Ags, the products of mutant or dysregulated genes in the malignant cells, will be expressed in a highly immunogenic form by semiallogeneic IL-2-secreting fibroblasts transfected with DNA from breast cancer cells. (Classic studies indicate that transfection of genomic DNA can stably alter both the genotype and the phenotype of the cells that take up the exogenous DNA.) To investigate this question, we transfected LM mouse fibroblasts (H-2^k) modified to secrete IL-2 with genomic DNA from a breast adenocarcinoma that arose spontaneously in a C3H/He mouse (H-2^k). To increase their nonspecific immunogenic properties, the fibroblasts were also modified before transfection to express allogeneic MHC determinants (H-2K^b). Afterward, the IL-2-secreting semiallogeneic cells were cotransfected with DNA from the spontaneous breast neoplasm, along with a plasmid (pHyg) conferring resistance to hygromycin. Pooled colonies of hygromycin-resistant cells were then tested in C3H/He mice for their immunotherapeutic properties against the growth of the breast neoplasm. The results indicated that tumor-bearing mice immunized with the transfected cells survived significantly longer than mice in various control groups. Similar beneficial effects were seen in C57BL/6 mice injected with a syngeneic breast carcinoma cell line (EO771) and semiallogeneic, IL-2-secreting fibroblasts transfected with DNA from EO771 cells. The immunity was mediated by CD8⁺ T cells since immunized mice depleted of CD8⁺ cells failed to resist tumor growth.

This article has been cited by other articles:

				I. O-Sullivan, A. Chopra, J. Carr, T. S. Kim, and E. P. Cohen Immunity to Growth Factor Receptor-Bound Protein 10, a Signal Transduction Molecule, Inhibits the Growth of Breast Cancer in Mice Cancer Res., April 1, 2008; 68(7): 2463 - 2470. [Abstract] [Full Text] [PDF]

				T. L. Whiteside, A. Gambotto, A. Albers, J. Stanson, and E. P. Cohen Human tumor-derived genomic DNA transduced into a recipient cell induces tumor-specific immune responses exvivo PNAS, July 9, 2002; 99(14): 9415 - 9420. [Abstract] [Full Text] [PDF]

				B. I. Loehr, R. Pontarollo, R. Rankin, L. Latimer, P. Willson, L. A. Babiuk, and S. van Drunen Littel-van den Hurk Priming by DNA immunization augments T-cell responses induced by modified live bovine herpesvirus vaccine J. Gen. Virol., December 1, 2001; 82(12): 3035 - 3043. [Abstract] [Full Text] [PDF]